HAVCR2 and B-cell chronic lymphocytic leukemia: Similarly, another study reported that, in patients with monoclonal B‐cell lymphocytosis (MBL)/CLL, interactions—including inhibitory T‐cell signals like BTLA/MIF–TNFRSF14, CTLA4–CD86, and LGALS9–HAVCR2—were downregulated after ibrutinib treatment [27].